Open AccessLupus erythematosus panniculitis in a 10-year-old female child with severe systemic lupus erythematosus
Author(s) -
Ruolin Zhang,
Xiqiang Dang,
Lanjun Shuai,
Qing He,
Xiaoqing He,
Zhao Yi
Publication year - 2018
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000009571
Subject(s) - medicine , dermatology , lupus erythematosus , systemic lupus erythematosus , panniculitis , systemic disease , systemic lupus , connective tissue disease , autoimmune disease , immunology , immunopathology , disease , antibody
Rationale: Lupus erythematosus panniculitis (LEP) is a rare subset of lupus erythematosus. The incidence of LEP in systemic lupus erythematosus (SLE) ranges from 2% to 5%. In the previous literature, most LEP patients were women aged from 20 to 60 years, while pediatric cases were rare, all of whom appeared on their own without SLE.A rare LEP in a 10-year-old female child with severe SLE is presented. Patient concerns: A 10-year-old girl was admitted to our hospital for marasmus and fatigue without other typical manifestations of SLE well before the appearance of skin lesions. The only proof to support the SLE is that we observed a weakly positive antinuclear antibody (ANA) in serum at the onset. Diagnoses: A 10-year-old girl diagnosed to the Division of Nephrology, Department of Pediatrics, the Second Xiangya Hospital, Central South University, for LEP with severe SLE. Interventions: The patient was administered with high-dose corticosteroids and cyclophosphamide. Outcome: The patient died of severe lung involvement despite the use of high-dose corticosteroids and cyclophosphamide. Lessons: This report highlights an unusual manifestation of LEP associated with SLE in a child. It also suggests that pediatricians should be aware of occult onset of SLE, such as unclear marasmus and fatigue found in this case. Repeat tests of antinuclear antibody and anti-double strand DNA antibody (anti-dsDNA) as well as renal biopsy in a timely manner will be effective to achieve early recognition and immediate treatment for saving lives.